Source:http://linkedlifedata.com/resource/pubmed/id/20549894
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
2010-6-16
|
pubmed:abstractText |
Graves' ophthalmopathy is a debilitating disease impairing the quality of life of affected individuals. The management of moderate-to-severe active Graves' ophthalmopathy is a major therapeutic challenge, and the treatment outcome is often unsatisfactory. We have carried out a retrospective study to assess the efficacy of combined orbital irradiation and systemic corticosteroids. Ten patients were included; all patients had received 20 Grays to the retrobulbar tissues in ten fractions, and oral or intravenous glucocorticoids. The main therapeutic outcome measures were the criteria of Donaldson and co-workers and a self-assessment evaluation. The quality of life outcome was also evaluated by the GO-QOL (Graves' ophthalmopathy quality of life) questionnaire. Seven patients (70%) demonstrated improvement in ocular parameters; the response was excellent in three cases, good in three cases and fair in one case. Three patients showed no response to the treatment. The self-assessment evaluation showed that 75% of patients were satisfied with the results of the treatment. Proptosis was the most responsive sign to radiation and steroids. A duration of the eye disease of more than 18 months was associated with less improvement and a higher failure of the treatment. Concerning the quality of life, the score for visual fonctionning was 882 +/- 18.2 after treatment, while the score for appearance was 63.3 +/- 23.3. In conclusion, a combination of orbital irradiation and systemic steroids is associated with 70% of favorable responses, but the quality of life is not restored in the same proportions and remains impaired after treatment.
|
pubmed:language |
fre
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
0023-9852
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
58
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
86-90
|
pubmed:meshHeading |
pubmed-meshheading:20549894-Adult,
pubmed-meshheading:20549894-Female,
pubmed-meshheading:20549894-Glucocorticoids,
pubmed-meshheading:20549894-Graves Ophthalmopathy,
pubmed-meshheading:20549894-Humans,
pubmed-meshheading:20549894-Methylprednisolone,
pubmed-meshheading:20549894-Quality of Life,
pubmed-meshheading:20549894-Radiotherapy Dosage,
pubmed-meshheading:20549894-Retrospective Studies
|
pubmed:articleTitle |
[Corticosteroids and radiotherapy in the treatment of Graves' ophthalmopathy].
|
pubmed:affiliation |
Service de Radiothérapie, CHU Hôtel-Dieu de France, Beyrouth, Liban. nasre@inco.com.lb
|
pubmed:publicationType |
Journal Article,
English Abstract
|